Recent Advances in Antibody–Drug Conjugates for Cancer Therapy

Dear Colleagues,

I am writing to invite you to contribute to a new Special Issue that I am guest editing for Pharmaceutics, titled “Antibody–Drug Conjugates (ADCs) for cancer treatment: from mechanistic insights to clinical translation”.

Antibody–drug conjugates (ADCs) continue to transform oncology, with rapid advances in linker technologies, site-specific conjugation, payload development and biomarker-guided patient selection. This Special Issue aims to highlight current innovations, mechanistic insights, and translational challenges of ADCs across solid malignancies. 

We are delighted to consider proposals for review papers and original articles on subjects including, but not limited to, the following:

• Foundations and technological advances in ADCs design, including antibody engineering and target selection; linker chemistry and drug release innovations; conjugation manufacturing; payload discovery and mechanisms. 
• Biomarkers and precision patient selection.
• Preclinical and translational development, including in vivo and ex vivo models; toxicity mechanisms and safety mitigation; interaction between ADCs and the immune system.
• Clinical development and therapeutic applications.
• Future directions and transformative concepts, including industry and regulatory perspectives.

If you are interested in contributing, I would be pleased to discuss potential topics or provide any additional information.

Thank you very much for considering this invitation. I hope to have the opportunity to include your work in this Special Issue.

Dr. Claudia Parisi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.